Cobra Biologics: against COVID-19 Company
Entity: Cobra Biologics
Category: Vaccine Development
Description: Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. They offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, they take pride in their manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries. Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply. Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given their people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market. They offer a broad range of integrated and stand-alone development services, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.
1. Project: OPENCORONA Consortium.
Summary: Cobra and Karolinska Institutet said March 30 they were awarded €3 million ($3.3 million) in emergency funding through the EU’s Horizon 2020 funding program for R&D and Phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium. In addition to Karolinska Institutet, partners in the consortium also include Karolinska University Hospital, the Public Health Agency of Sweden (FoHM), IGEA, Adlego, and Giessen University.
2. Project: BIA industry-led vaccine manufacturing taskforce
Summary: Working closely with the Government and reporting directly into the Chief Scientific Advisor, Sir Patrick Vallance. The vaccine manufacturing group will consider any COVID-19 vaccines or therapies which emerge, regardless of whether the vaccine or therapy is UK or internationally based and look to help where it can. The industry-led vaccine manufacturing group began from conversations between Steve Bates OBE, Chief Executive of the BIA and key members of the life sciences manufacturing community, in early March. From these discussions, the BIA issued a UK manufacturing capacity audit which assessed UK capability to rapidly scale up any vaccine candidates and COVID-19 therapies. The group is a collaboration of the public sector, private sector companies, academia and universities, building on the UK’s world leading science base and is chaired by Ian McCubbin OBE, former VP for Global Manufacturing and Supply at GlaxoSmithKline.
The group is currently supporting the Jenner Institute’s adenovirus vaccine candidate at the University of Oxford, led by Dr Sandy Douglas, with Professor Sarah Gilbert and the Clinical BioManufacturing Facility. There has been a successful bid to UKRI in partnership with BIA members Pall, Fujifilm, Cobra, Cell and Gene Therapy Catapult, the Vaccines Manufacturing Innovation Centre (VMIC) and Oxford Biomedica to develop rapid scale up of such a vaccine. The group is also supporting the work of Imperial College London, led by Professor Robin Shattock, where the team is working on an mRNA vaccine.
3. Project: Vaccine ChAdOx1 nCov-19
Summary: The University of Oxford’s ChAdOx1 nCoV-19 is an adenovirus vaccine vector developed by the university’s Jenner Institute. The university is testing the vaccine in a clinical trial planned to be conducted in the Thames Valley Region. UK-based gene and cell therapy group Oxford Biomedica has become part of a consortium focussed on the development, scale-up and production of a Covid-19 coronavirus vaccine candidate; led by Jenner Institute, University of Oxford, the consortium involves the Vaccines Manufacturing and Innovation Centre (VMIC), Cobra Biologics, Pall Life Sciences and Halix. Vaccine ChAdOx1 nCov-19, studied in a trial in the UK, will assess vaccine candidate’s safety and ability to induce an immune response against the novel coronavirus. Based on ChAdOx1 adenoviral vector technology developed at the Jenner Institute, the vaccine candidate was able to induce a strong immune response from one dose in preclinical and clinical trials to date.
+ Investors:
Horizon 2020
Innovate UK
.jpg)
.jpg)
.jpg)
